Ascendis Pharma A/S (ASND)

Market Cap	14.98B
Revenue (ttm)	1.20B +113.4%
Net Income	847.43M
EPS	13.38
Shares Out	65.67M
PE Ratio	17.02
Forward PE	32.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	783,210
Open	229.66
Previous Close	227.87
Day's Range	226.84 - 230.73
52-Week Range	203.80 - 282.15
Beta	0.49
Analysts	Strong Buy
Price Target	309.22 (+35.61%)
Est. Earnings	Nov 11, 2026

About ASND

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 28, 2015
• Employees: 1,189
• Stock Exchange: Nasdaq
• Ticker Symbol: ASND
• Website: https://ascendispharma.com

Financial Performance

In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.

Financial numbers in EUR

Analyst Summary

According to 20 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $309.22, which is an increase of 35.61% from the latest price.

Price Target

$309.22

(35.61% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 5, 2026

Data Sources Report a data error